Health-related quality of life was generally superior with immunotherapy plus chemotherapy vs chemotherapy alone.
Disease-free survival was better with atezolizumab than with best supportive care.
Overall survival was significantly longer for patients who received sintilimab plus chemotherapy than for those who received placebo plus chemotherapy.
Adding ipilimumab to pembrolizumab did not improve survival outcomes.
Furmonertinib improved progression-free survival and appeared safer than gefitinib in a phase 3 trial.
Camrelizumab improved overall survival, even when adjusting for crossover.